Header

Melanoma Clinical Trials

Category:Adult
Status:Active

Displaying all 17 trials

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. T...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 15-012

Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma

This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases from Melanoma. The names of the study interventions involved in this study are: - Ip...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 16-136

Dendritic Cell Activating Scaffold in Melanoma

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investi...

Diagnosis: Melanoma

Phase: 1

Protocol Number: 12-306

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The intervention...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-030

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with P...

Diagnosis: GYN: Endometrial/Uterine Cancer, Melanoma, Pancreatic Cancer, Breast: Early Stage Disease

Phase:

Protocol Number: 16-491

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: - Pembrolizumab (Keytruda) - Trametinib...

Diagnosis: Melanoma

Phase:

Protocol Number: 16-642

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-280

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

In this study, participants with advanced melanoma will be treated with pembrolizumab (MK-3475) and their tumors and blood will be analyzed for changes related to pembrolizumab therapy.

Diagnosis: Melanoma

Phase:

Protocol Number: 15-487

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.

Diagnosis: Melanoma

Phase:

Protocol Number: 17-526

CAVATAKĀ® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.

Diagnosis: Melanoma

Phase:

Protocol Number: 17-601

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or ...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-269

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.

Diagnosis: Melanoma

Phase:

Protocol Number: 17-383

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 muta...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-307

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatm...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-460

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventio...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-656

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: - Itacitinib (INCB039110) - Dabrafenib - Trametinib

Diagnosis: Melanoma

Phase:

Protocol Number: 17-380

'